A nine-protein plasma signature is predictive of kidney events and mortality in individuals with a high-risk APOL1 genotype and preserved estimated glomerular filtration rate, outperforming existing clinical and genetic risk tools and providing a biologically plausible marker set for early intervention and trial enrichment.